WilmerHale Advises Georgiamune on $75M Series A Financing

  • 8.14.2023

On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases. General Catalyst and Parker Institute for Cancer Immunotherapy (PICI) co-led the round, while Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, and Verition Fund Management provided additional funding.

The WilmerHale team representing Georgiamune was led by Rosemary Reilly, Frances Mosley, Alex Bloom and Jane Cha